FDA spotlights innovation in 3-D imaging

Breast cancer detection may soon leave 2-D mammography in the dust, embracing instead a more comprehensive diagnostic tool: 3-D technology. By embracing the future of 3-D breast tomosynthesis, doctors can pinpoint the size and location of cancer tumors in dense breast tissue with more accuracy. This is done by creating an artificial 3-D image of the breast from a limited set of 2-D images, revealing sections of the breast that can be hidden by overlapping tissue in standard 2-D mammograms. Story

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.